27 - Text section (intro)
Invest
Why invest in Sothema?
Sothema offers a unique exposure to the structural growth of the regional pharmaceutical sector, driven by a leading industrial platform, a diversified therapeutic portfolio, continuous innovation momentum and an ambitious, disciplined development strategy to create sustainable value for patients and shareholders.
3 - Carte 3 colonne avec picto
50 years of excellence
A diversified portfolio driven by continuous innovation
10
Specialized industrial units in Morocco and Senegal
+350
Commercialized products covering most therapeutic areas
+35
Export Markets
+50
Strategic partnerships with international pharmaceutical companies
36 - Table
Our financial performance
| In MMAD | 2022 | 2023 | 2024 | 2025 RF | TCAM 23-25 |
| Consolidated sales | 2 302 | 2 486 | 2 816 | 3 318 | 15,5% |
| EBITDA consolidated | 498 | 490 | 600 | 725 | 21,7% |
| EBITDA margin (%) | 21,6% | 20% | 21% | 22% |
- |
| Net Income - Group Share (MAD Million) | 267 | 263 | 315 | 418 |
- |
27 - Text section (intro)
50 YEARS OF EXCELLENCE
An integrated pharmaceutical platform built on 50 years of industrial excellence
Founded in 1976, Sothema has established itself as one of the leading industrial pharmaceutical players in the region, thanks to an integrated model combining industrial expertise, international partnerships and leadership in its domestic market.
After 50 years of development, the Group has built a comprehensive industrial platform covering the manufacture, development and distribution of drugs, enabling it to capture value across the entire pharmaceutical chain. This industrial infrastructure positions Sothema as a privileged partner for international laboratories wishing to develop their regional presence.
13 - content left + image
Continuous innovation
and an upmarket shift toward high-value segments
PORTFOLIO
A diversified portfolio and continuous innovation drive
Sothema develops and markets a portfolio of medicines covering several therapeutic areas essential to public health, including cardiovascular disease, diabetes and metabolic pathologies, oncology and immunotherapy.
The Group is also pursuing a gradual move upmarket towards higher value-added therapeutic segments, while maintaining solid positions in essential medicines. This strategy enables Sothema to combine volume growth and value creation, while reinforcing the sophistication of its portfolio.
30 - 3-column card with picto or number
Listed on the Casablanca Stock Exchange
A steady growth trajectory
PERFORMANCE
Solid financial performance and disciplined value creation
Sothema has demonstrated steady growth and robust profitability in recent years, supported by rigorous management and disciplined capital allocation.
History of sustained growth at c. 13% per annum
Resilient operating margins: c. 25% EBITDA margin
A controlled balance sheet structure offering strategic flexibility
Policy of regular dividend distribution
8 - Picture cards and small cards
BUSINESS MODEL
A balanced, value-generating business model
Sothema's business model is based on three complementary pillars, ensuring diversified revenue streams and operational resilience. This organization enables the Group to create value at different levels of the pharmaceutical chain, while optimizing the use of its industrial capacities.
Generic and biosimilars products
The Group develops and manufactures a wide range of generic and own-brand medicines, meeting the growing need for accessible, quality treatments.
Licensed products
Sothema produces and commercializes innovative drugs under license from international pharmaceutical companies, bringing cutting-edge therapies to market.
Contract Manufacturing
Thanks to its high-performance industrial facilities, Sothema also offers manufacturing services on behalf of national and international laboratories.
Publications - Last 3 ads
28 - Connected people
TO FIND OUT MORE
Discover the Group
Explore the pillars that shape Sothema's identity, expertise and impact.